The effects of ursodeoxycholic acid on ileal absorption of bile acids and on serum bile acid and lipoprotein concentrations were studied. Eight healthy subjects were investigated. The y emitting bile acid analogue, SeHCAT, was given orally and its fractional catabolic rate and seven day retention were assessed by repeated external counting over the upper abdomen during the next seven days. Ursodeoxycholic acid was then given oraily at a dose of 15 mg/kg! day for three weeks and the study was repeated during treatment. The fractional catabolic rate 
The primary bile acids, cholic acid and chenodeoxycholic acid, are formed from cholesterol in the liver and stored in the gall bladder in the fasting state. ' In response to a meal, bile acids are excreted into the intestine where they contribute to the efficient absorption of dietary fat and cholesterol. The secondary bile acids, deoxycholic acid and lithocholic acid, are the result of dehydroxylation of cholic acid and chenodeoxycholic acid by intestinal bacteria. The reabsorption of bile acids is very efficient, particularly because of active uptake in the distal ileum. The synthesis of bile acids is regulated by a homeostatic mechanism in which bile acids returning to the liver from the intestine inhibit their own synthesis. 2 The demand for hepatic cholesterol increases where bile acid synthesis is stimulated, and this is met by an increased cholesterol synthesis as well as by an increased expression of the low density lipoprotein receptors.' Thus, disturbances in bile acid kinetics may influence low density lipoprotein catabolism in several clinical situations.
Ursodeoxycholic acid, which is the 73 epimer of chenodeoxycholic acid, is a minor constituent of the normal bile pool acid in man. 4 Its clinical use has become important in the treatment of cholesterol gall stones,4 primary biliary cirrhosis,5 and sclerosing cholangitis. Serum bile acid analysis during ursodeoxycholic acid administration showed a significant increase in the ursodeoxycholic acid concentration (7-87 (2-67) v 0 34 (0-24) ,umol/l; p<0001) and an even greater one during 'high' dose treatment (1l134 (4 13) v 0-27 (0 24) [tmol/l; p<0005), while there was no significant change in the concentrations of the other bile acids (Table III) .
During treatment with 15 mg/kg/day, the only significant change in plasma lipids was a decrease in the total cholesterol concentration from 5-79 (Table IV) . During 'high' dose ursodeoxycholic acid administration there was a further significant decrease from the basal values in the total cholesterol concentration (from [6] [7] [8] to Although the molecular properties ofthe intestinal bile acid carrier are not yet known in detail, physiological studies have indicated that the transport system has a preference for trihydroxy bile acids and that it is working relatively close to saturation under physiological conditions.' 19 An increased load of exogenous ursodeoxycholic acid should thus preferentially interfere with the enterohepatic circulation of cholic acid. In accordance with this contention, the excretion of cholic acid was increased somewhat more than that of chenodeoxycholic acid during short term administration of ursodeoxycholic acid to patients with ileostomy.2" Such an exclusion of cholic acid (and chenodeoxycholic acid) from the enterohepatic circulation would result in reduced amounts of primary bile acids being returned to the liver via the portal venous circulation. Since ursodeoxycholic acid does not seem to suppress bile acid synthesis72' or the activity of its rate limiting enzyme, cholesterol 7 a-hydroxylase,22 such treatment would result in an increase in bile acid production in order to maintain the pool sizes of these bile acids.
A second new finding in this study emerges from the determination of individual serum bile acid concentrations (Table III) 
